Search results

Selected filters:

News
Life Sciences

Article type

Topic

Sector

Regions

Year

124 results found for your search

Sort options
31 July 2015

The companies that abandon most US and EPO patents – and shoulder much responsibility for raising quality

In the latest issue of IAM magazine – available for subscribers to view online from today – Matthew Beers and Maria Lazarova of Ocean Tomo take a deep-dive look at patent abandonments data from both the USPTO and EPO. The full article contains a…

17 July 2015

The Kyle Bass pharma patent IPR strategy looks to be a lot more sophisticated and long-term than many think

Last week we published an interview with Kyle Bass, the hedge fund investor who together with Erich Spangenberg, has petitioned to challenge a series of pharmaceutical patents through the inter partes review (IPR) process at the Patent Trial and…

16 July 2015

The Innovation Act is pulled, but uncertainty lingers and that’s bad for business

The Innovation Act was dramatically pulled from consideration last night just days before a vote on it was expected in the House of Representatives. It is now unlikely that the proposed legislation will be considered again until after the summer…

10 July 2015

Big pharma is terrified of what I am doing, but I am bringing greater clarity to the market, says Bass

This time a few months ago no-one inside the world of IP would have given Hayman Capital founder and manager Kyle Bass a second thought, unless they were one of his investors. Now, though, his name is on everyone’s lips. Since teaming up with Erich…

22 June 2015

Pressure intensifies on India over software and pharma patent protection in key Asian trade negotiations

The proposed Trans-Pacific Partnership (TPP) has grabbed its fair share of headlines in both Asia and the Americas after the US House of Representatives’ dramatic rejection of a key part of the package. But although intellectual property features…

18 June 2015

US patent leadership may be over and the IP market is changing, but opportunities abound

Unsurprisingly, one of the key themes at this year’s IPBC in San Francisco was that the US market is in a state of serious flux. There was no consensus on whether the pendulum has swung too far against the interests of patent owners – your views on…

16 June 2015

Patent values about to climb, heroic inventors, the US's patent failure, hope for SMEs, and much more at the IPBC

The first full day of the IPBC Global in San Francisco is now done and dusted. Here, IAM’s editorial team – Joff Wild, Richard Lloyd, Jack Ellis and Sara Jayne Clover – pick out a few of the highlights from the sessions and from the conversations…

05 June 2015

US patent reform passes a key Congressional hurdle but still faces significant challenges

It is a truism of US politics that one of the hardest things in Washington DC is getting a bill to the floor of the Senate for a vote. In that respect patent reform took a major step forward yesterday as the PATENT Act, the bill introduced last…

25 May 2015

Patent reform could do terrible damage to our many successful programmes, says Columbia's tech transfer chief

Orin Herskowitz is head of technology transfer at Columbia University, one of the most respected and successful university licensing operations in the United States. His role not only means that he is plugged into the steady stream of new technology…

19 May 2015

It's not all doom and gloom for pharmaceutical innovators in India

Merck has become the latest foreign pharmaceutical innovator to notch a patent win in an Indian court. Last Friday, the country’s Supreme Court enjoined Glenmark Generics from selling new low-cost versions of diabetes drugs Januvia and Janumet …

18 May 2015

The USPTO has the power to create a much more equitable IPR process; and it should do so

Since the America Invents Act overhauled the re-examination process, we have written regularly about the impact that the new procedures, and inter partes reviews in particular, have had on the patent market. Essentially, they have become a new tool…

15 May 2015

Compulsory licensing is not just a risk factor in India and other emerging markets

The following is a brief extract from a letter which a national legislator sent to a member of the cabinet earlier this week: “I ask you to utilise federal law… to break the patents on these drugs to authorise third parties to manufacture or…

08 May 2015

It’s not just big pharma that wants to see IPR reform in US patent legislation

For over an hour yesterday, as the Senate Judiciary Committee hearing on the recently introduced PATENT Act unfolded, it seemed like we were in patent fantasyland. Except for some predictable comments from the deputy general counsel of pharma giant…

08 May 2015

More evidence that Chinese patent values could rise as Apple win shows increasing court focus on quality

On the sidelines of the INTA annual meeting in San Diego, IAM attended a seminar on the last year’s changes to trademark law in China. There was a nice bonus at the end, though, in the form of a discussion of patent litigation trends from Wan Hui Da…

30 April 2015

New Senate bill pushes patent reform a step closer to consensus, but there is a long way to go

The latest attempts to introduce new legislative patent reform in the US took its most significant step yesterday when the Protecting American Talent and Entrepreneurship (PATENT) Act was introduced in the Senate. With the backing of Senate…